🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,522 results for “solution” Clear

  1. GTX/UX Diluent and Flush Solution, GTX-102, ELLIOTTS B SOLUTION (buffered intrathecal electrolyte/dextrose injection)

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 3 small molecule active

    1 trial

  2. Gazyva Placebo, Gazyvaro 1,000 mg concentrate for solution for infusion.

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  3. Gazyvaro 1,000 mg concentrate for solution for infusion., Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets, Chlorambucil 2 mg tablets

    Lacuna Pharma Pty Ltd

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  4. Gazyvaro 1,000 mg concentrate for solution for infusion., Chlorambucil 2 mg tablets, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion., Venclexta, Venclyxto, Venclexta, Venclyxto, Venclexta, Venclyxto

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  5. Gazyvaro 1,000 mg concentrate for solution for infusion., Prograf 1 mg Hartkapseln, Prograf 0,5 mg Hartkapseln, Prograf 5 mg Hartkapseln

    Hoffmann-La Roche

    Primary Membranous Nephropathy (pMN)

    phase 3 small molecule active

    1 trial

  6. Gazyvaro 1,000 mg concentrate for solution for infusion., Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg hard capsules, Venclyxto 10 mg film-coated tablets, Calquence 100 mg hard capsules

    AstraZeneca AB

    Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  7. Gemcitabine 38 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion.

    Gilead Sciences Pty Limited

    PD-L1 Positive Metastatic Triple-Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  8. Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Revlimid 25 mg hard capsules, Epcoritamab (GEN3013), Epcoritamab (GEN3013), Oxaliplatin 5mg/ml Concentrate for Solution for Infusion, Revlimid 5 mg hard capsules, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Truxima 500 mg concentrate for solution for infusion, Revlimid 20 mg hard capsules, Truxima 100 mg concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  9. Gemcitabine Eugia 40 mg/ml solution à diluer pour perfusion, RILVEGOSTOMIG, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Hihg risk of cholangiocarcinoma intra hépatic resectable

    phase 3 small molecule active

    1 trial

  10. Giapreza 2.5 mg/ml concentrate for solution for infusion, SODIUM CHLORIDE SOLUTION 0.9%

    PAION Pharma GmbH

    refractory hypotension in distributive shock

    phase 3 small molecule active

    1 trial

  11. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab

    Janssen-Cilag International N.V.

    Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  12. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  13. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, STELARA 90 mg solution for injection in pre-filled syringe, Placebo for Ustekimumab, Placebo for Guselkumab, STELARA 130 mg concentrate for solution for infusion

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  14. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Type Psoriasis

    phase 3 small molecule active

    1 trial

  15. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  16. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  17. Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 2 mL PFS Placebo, Guselkumab 0.5 mL Varioject Placebo, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  18. Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab 2 mL PFS Placebo

    Janssen-Cilag International N.V.

    Moderate to Severly Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  19. Guselkumab, Placebo 0.5ml equivalent, Guselkumab- Solution for infusion- 10 mg/ml, Placebo 2.0ml equivalent, Guselkumab, Placebo 1.0ml equivalent, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  20. Guselkumab- Solution for infusion- 10 mg/ml, Placebo to Guselkumab, Placebo to Guselkumab solution for injection in pre-filled syringe -100 mg/ml, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Placebo to Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Fistulizing perianal Crohn's Disease

    phase 3 small molecule active

    1 trial

  21. HOLOXAN 2000 mg, poudre pour usage parentéral, DETICENE 100 mg, poudre et solvant pour solution pour perfusion, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    The George Institute

    Resectable, non-metastatic soft-tissue sarcoma (STS)

    phase 3 small molecule active

    1 trial

  22. HUMAN NORMAL IMMUNOGLOBULIN (IV), Placebo for empasiprubart- solution for IV infusion, Placebo for IVIg - solution for IV infusion, ARGX-117

    argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  23. HYCAMTIN 4 mg powder for concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  24. HYDROXYCHLOROQUINE, METHOTREXATE, Remsima 120 mg solution for injection in pre-filled pen, METHOTREXATE, IBUPROFEN, Placebo (To evaluate the efficacy and safety of CT-P13, and mainatain blindness during the study, Placebo will be administered.), PARACETAMOL, FOLIC ACID, HYDROCORTISONE

    Celltrion Healthcare Australia Pty Ltd

    Rheumatoid arthritis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources